Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.

ABSTRACT:

Background

Aromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxicities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that nonpersistence with AI therapy was associated with symptoms that were present before treatment initiation.

Methods

Postmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associations between basel

SUBMITTER: Kidwell KM 

PROVIDER: S-EPMC4126845 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature